ReviewBrain sciences2024
Pathophysiology to Risk Factor and Therapeutics to Treatment Strategies on Epilepsy.
Review in Brain sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 23 citations in OpenAlex.
- Clinical application of artificial intelligence technology in epilepsy.Acta epileptologica · 2026Review
- Curcumin nanoformulations in drug-resistant epilepsy: A mini review on mechanisms, preclinical evidence, and translational challenges.Molecular biology reports · 2026Review
- Investigating the Effect of Low Molecular Weight Heparin, Enoxaparin, on Pentylenetetrazole (PTZ)-Induced Neuronal Damage in C6 and HT-22 Cell Lines.Cell biochemistry and biophysics · 2026Article
- Syringic Acid as a Potential Anticonvulsant Agent: Mechanistic Perceptions into Nitrite and Oxidative Stress Balance in the Prefrontal Cortex.Current pharmaceutical design · 2026Article
- Efficacy and safety of levetiracetam intravenous infusion combined with midazolam continuous pump infusion for stepwise emergency treatment of convulsive status epilepticus in children: a retrospective cohort study.American journal of translational research · 2026Article
- Ketogenic Diet and Neuroinflammation: Implications for Neuroimmunometabolism and Therapeutic Approaches to Refractory Epilepsy.Nutrients · 2024Review
- Adeno-Associated Viral Vectors in the Treatment of Epilepsy.International journal of molecular sciences · 2024Review
- Potential Neuroprotective Effects ofNutrients · 2024Review
- Repositioning pinacidil and its anticonvulsant and anxiolytic properties in murine models.Scientific reports · 2024Article
- Association ofGenes · 2024Article
- Composition and influencing factors of hospitalization expenses for epilepsy patients based on path analysis.International journal for equity in health · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epilepsy represents a condition in which abnormal neuronal discharges or the hyperexcitability of neurons occur with synchronicity, presenting a significant public health challenge. Prognostic factors, such as etiology, electroencephalogram (EEG) abnormalities, the type and number of seizures before treatment, as well as the initial unsatisfactory effects of medications, are important considerations. Although there are several third-generation antiepileptic drugs currently available, their multiple side effects can negatively affect patient quality of life. The inheritance and etiology of epilepsy are complex, involving multiple underlying genetic and epigenetic mechanisms. Different neurotransmitters play crucial roles in maintaining the normal physiology of different neurons. Dysregulations in neurotransmission, due to abnormal transmitter levels or changes in their receptors, can result in seizures. In this review, we address the roles played by various neurotransmitters and their receptors in the pathophysiology of epilepsy. Furthermore, we extensively explore the neurological mechanisms involved in the development and progression of epilepsy, along with its risk factors. Furthermore, we highlight the new therapeutic targets, along with pharmacological and non-pharmacological strategies currently employed in the treatment of epileptic syndromes, including drug interventions employed in clinical trials related to epilepsy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.